Key result
Among 636 hospitalized patients with HFrEF in the Philippines, utilization of guideline-directed medical therapy was suboptimal (54.9% for ACEI/ARBs, 47.5% for beta-blockers) with 3.9% mortality.
Why the study?
This study aimed to describe the characteristics, treatment pattern trends, and in-hospital outcomes of patients with HFrEF enrolled in the Heart Failure Registry of the Philippine Heart Association.
Observational (n=636)
Yes
Guideline-directed medical therapy for HFrEF remains significantly underutilized in the Philippines, highlighting the need for continuous educational programs and performance monitoring.
Answers are grounded in this paper and cite their sources.
Registry data may guide Philippine HFrEF care; leaves open need for randomized outcome trials.
In 2014, the Optimize Heart Failure Care Programme was introduced to 12 cardiology training institutions in the Philippines through partnership with the Philippine Heart Association Council on Heart Failure.The Heart Failure Registry, an ongoing, prospective, multicentre, observational study of patients, is part of this Programme.This study aimed to describe the characteristics, trends in treatment patterns and in-hospital outcomes of heart failure patients with reduced ejection fraction (HFrEF) (ejection fraction of 50% or lower) enrolled in the Heart Failure Registry from 2014 to 2018.The registry included all hospitalised adult patients who fulfill the Framingham criteria for the diagnosis of HF.During the study period, the Heart Failure Registry enrolled 636 patients with HFrEF, with a mean age of 56.7 ± 15.2 years; 60.1% were males.The Heart Failure Registry showed that the use of ACEI/ARBs, beta-blockers, MRAs and ivabradine in patients with HFrEF is suboptimal.Just over half of patients were given angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) (54.9%), while 47.5% received beta-blockers and 26.5% received mineralocorticoid receptor antagonists (MRA).Only 6.6% of patients (6.6%) received ivabradine.The overall in-hospital mortality rate was 3.9%.The utilisation rates of guideline-directed pharmacotherapy, particularly for ACEI/ARBs and beta-blockers, followed the scale of educational activities of the Optimize Heart Failure Care programme.Hence, continuation of the programme, including its educational components, and continuous monitoring of performance measures is recommended.
No takes yet. Share an insight, caveat, or question.
Reyes et al. (2020) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=636). Guideline-directed pharmacotherapy was evaluated on Prescription rates of guideline-directed pharmacotherapy and in-hospital outcomes. Among 636 hospitalized patients with HFrEF in the Philippines, utilization of guideline-directed medical therapy was suboptimal (54.9% for ACEI/ARBs, 47.5% for beta-blockers) with 3.9% mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: